Seres Therapeutics (MCRB) Misses Q2 EPS by 24c
Tweet
Share
E-mailGet Alerts MCRB Hot Sheet
Join SI Premium – FREE
Seres Therapeutics (NASDAQ: MCRB) reported Q2 EPS of ($0.70), $0.24 worse than the analyst estimate of ($0.46). Revenue for the quarter came in at $3 million versus the consensus estimate of $4.2 million.
For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CrowdStrike shares jump on earnings beat, raised outlook
- Materialise NV (MTLS) Reports Q2 EPS of EUR0.06
- NVIDIA (NVDA) Tops Q2 EPS by 14c, Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
